AIMS: To evaluate trends in use of stop-smoking medications (SSMs) before and after varenicline (Chantix™) was introduced to the market-place in the United States, and to determine whether varenicline reached segments of the population unlikely to use other SSMs. DESIGN: Cohort survey. SETTING: United States. PARTICIPANTS: A nationally representative sample of adult smokers in the United States interviewed as part of the International Tobacco Control Four Country Survey between 2004 and 2011. Primary analyses used cross-sectional data from 1737 smokers who attempted to quit (∼450 per wave). MEASUREMENTS: Reporting an attempt to quit smoking; use of each of the following types of SSMs for the purpose of quitting smoking: nicotine gum, nicotine patch, other nicotine replacement therapy, bupropion and varenicline. FINDINGS: There was a significant increase in the rate of use of any SSM among quit attempters across the study period [odds ratio (OR) = 1.15, 95% confidence interval (CI) = 1.10-1.21 per year]. This increase was largest after varenicline was introduced (OR = 1.16, 95% CI = 1.07-1.26 per year); however, there was a decline in nicotine patch use during this time (OR = 0.87, 95% CI = 0.76-0.99 per year). Varenicline users were generally similar to users of other SSMs but differed from those who did not use any SSMs, in that they tended to be older (OR = 5.46, P = 0.024), to be white (OR = 2.33, P = 0.002), to have high incomes (OR = 1.85, P = 0.005), to have high nicotine dependence prior to quitting (OR = 2.40, P = 0.001) and to have used medication in the past (OR = 3.29, P < 0.001). CONCLUSIONS: The introduction of varenicline in the United States coincided with a net increase in attempts to quit smoking and, among these, a net increase in use of stop-smoking medications. The demographic profile of varenicline users is similar to the profile of those who use other stop-smoking medications and different from the profile of those who attempt to quit without any medication.
AIMS: To evaluate trends in use of stop-smoking medications (SSMs) before and after varenicline (Chantix™) was introduced to the market-place in the United States, and to determine whether varenicline reached segments of the population unlikely to use other SSMs. DESIGN: Cohort survey. SETTING: United States. PARTICIPANTS: A nationally representative sample of adult smokers in the United States interviewed as part of the International Tobacco Control Four Country Survey between 2004 and 2011. Primary analyses used cross-sectional data from 1737 smokers who attempted to quit (∼450 per wave). MEASUREMENTS: Reporting an attempt to quit smoking; use of each of the following types of SSMs for the purpose of quitting smoking: nicotine gum, nicotine patch, other nicotine replacement therapy, bupropion and varenicline. FINDINGS: There was a significant increase in the rate of use of any SSM among quit attempters across the study period [odds ratio (OR) = 1.15, 95% confidence interval (CI) = 1.10-1.21 per year]. This increase was largest after varenicline was introduced (OR = 1.16, 95% CI = 1.07-1.26 per year); however, there was a decline in nicotine patch use during this time (OR = 0.87, 95% CI = 0.76-0.99 per year). Varenicline users were generally similar to users of other SSMs but differed from those who did not use any SSMs, in that they tended to be older (OR = 5.46, P = 0.024), to be white (OR = 2.33, P = 0.002), to have high incomes (OR = 1.85, P = 0.005), to have high nicotine dependence prior to quitting (OR = 2.40, P = 0.001) and to have used medication in the past (OR = 3.29, P < 0.001). CONCLUSIONS: The introduction of varenicline in the United States coincided with a net increase in attempts to quit smoking and, among these, a net increase in use of stop-smoking medications. The demographic profile of varenicline users is similar to the profile of those who use other stop-smoking medications and different from the profile of those who attempt to quit without any medication.
Authors: M E Thompson; G T Fong; D Hammond; C Boudreau; P Driezen; A Hyland; R Borland; K M Cummings; G B Hastings; M Siahpush; A M Mackintosh; F L Laux Journal: Tob Control Date: 2006-06 Impact factor: 7.552
Authors: G T Fong; K M Cummings; R Borland; G Hastings; A Hyland; G A Giovino; D Hammond; M E Thompson Journal: Tob Control Date: 2006-06 Impact factor: 7.552
Authors: David Gonzales; Stephen I Rennard; Mitchell Nides; Cheryl Oncken; Salomon Azoulay; Clare B Billing; Eric J Watsky; Jason Gong; Kathryn E Williams; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Karin A Kasza; Andrew J Hyland; Ron Borland; Ann D McNeill; Maansi Bansal-Travers; Brian V Fix; David Hammond; Geoffrey T Fong; K Michael Cummings Journal: Addiction Date: 2012-08-14 Impact factor: 6.526
Authors: Jaimee L Heffner; Kristin E Mull; Noreen L Watson; Jennifer B McClure; Jonathan B Bricker Journal: Nicotine Tob Res Date: 2020-08-24 Impact factor: 4.244
Authors: Su Fen Lubitz; Alex Flitter; E Paul Wileyto; Douglas Ziedonis; Nathaniel Stevens; Frank Leone; David Mandell; John Kimberly; Rinad Beidas; Robert A Schnoll Journal: Nicotine Tob Res Date: 2020-08-24 Impact factor: 4.244
Authors: Rae A Littlewood; Eric D Claus; Claire E Wilcox; Jessica Mickey; Pamela B Arenella; Angela D Bryan; Kent E Hutchison Journal: Psychopharmacology (Berl) Date: 2017-09-09 Impact factor: 4.530
Authors: Robert A Schnoll; Brian Hitsman; Sonja Blazekovic; Anna Veluz-Wilkins; E Paul Wileyto; Frank T Leone; Janet E Audrain-McGovern Journal: Drug Alcohol Depend Date: 2016-06-25 Impact factor: 4.492
Authors: Ruifeng Chen; John P Pierce; Eric C Leas; Martha M White; Sheila Kealey; David R Strong; Dennis R Trinidad; Tarik Benmarhnia; Karen Messer Journal: Am J Epidemiol Date: 2020-12-01 Impact factor: 4.897
Authors: Mackenzie Hosie Quinn; Matthew Olonoff; Anna-Marika Bauer; Erica Fox; Nancy Jao; Su Fen Lubitz; Frank Leone; Jacqueline K Gollan; Robert Schnoll; Brian Hitsman Journal: Nicotine Tob Res Date: 2022-01-01 Impact factor: 5.825